Compare Stocks: SANA, TNGX, TLX, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$20.27 -1.8%	$26.10	$16.24 ▼ $38.35	$3.84B	0.37	2.88 million shs	1.97 million shs
SANA Sana Biotechnology	$3.67 -2.7%	$3.35	$2.61 ▼ $6.55	$1.13B	2.16	2.47 million shs	1.96 million shs
TLX Telix Pharmaceuticals	$12.33 +3.0%	$10.67	$6.28 ▼ $12.60	$4.07B	-0.24	108,278 shs	85,165 shs
TNGX Tango Therapeutics	$25.65 +0.3%	$28.81	$6.25 ▼ $34.39	$4.31B	1.16	2.30 million shs	2.17 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	-1.84%	+5.13%	-21.04%	-26.42%	-45.11%
SANA Sana Biotechnology	-2.65%	+7.62%	+2.80%	+19.54%	+10.71%
TLX Telix Pharmaceuticals	+3.01%	+15.88%	+11.89%	+16.76%	+10.29%
TNGX Tango Therapeutics	+0.27%	-11.55%	-13.49%	+24.76%	+272.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LEGN Legend Biotech	$20.27 -1.8%	$26.10	$16.24 ▼ $38.35	$3.84B	0.37	2.88 million shs	1.97 million shs
SANA Sana Biotechnology	$3.67 -2.7%	$3.35	$2.61 ▼ $6.55	$1.13B	2.16	2.47 million shs	1.96 million shs
TLX Telix Pharmaceuticals	$12.33 +3.0%	$10.67	$6.28 ▼ $12.60	$4.07B	-0.24	108,278 shs	85,165 shs
TNGX Tango Therapeutics	$25.65 +0.3%	$28.81	$6.25 ▼ $34.39	$4.31B	1.16	2.30 million shs	2.17 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LEGN Legend Biotech	-1.84%	+5.13%	-21.04%	-26.42%	-45.11%
SANA Sana Biotechnology	-2.65%	+7.62%	+2.80%	+19.54%	+10.71%
TLX Telix Pharmaceuticals	+3.01%	+15.88%	+11.89%	+16.76%	+10.29%
TNGX Tango Therapeutics	+0.27%	-11.55%	-13.49%	+24.76%	+272.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LEGN Legend Biotech	2.47	Hold	$52.29	157.95% Upside
SANA Sana Biotechnology	2.67	Moderate Buy	$9.50	158.86% Upside
TLX Telix Pharmaceuticals	2.63	Moderate Buy	$20.40	65.45% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.31	68.84% Upside

Current Analyst Ratings Breakdown

Latest SANA, TNGX, TLX, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	LEGN Legend Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $49.00
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$32.00 ➝ $35.00
8/12/2026	LEGN Legend Biotech	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$75.00 ➝ $40.00
8/12/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$80.00 ➝ $78.00
8/12/2026	LEGN Legend Biotech	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$29.00 ➝ $24.00
8/12/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$59.00 ➝ $58.00
8/12/2026	LEGN Legend Biotech	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$75.00 ➝ $40.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LEGN Legend Biotech	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LEGN Legend Biotech	$1.03B	3.66	N/A	N/A	$5.43 per share	3.73
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A
TLX Telix Pharmaceuticals	$803.79M	5.21	$0.04 per share	283.89	$1.23 per share	10.02
TNGX Tango Therapeutics	$62.38M	69.33	N/A	N/A	$2.57 per share	9.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LEGN Legend Biotech	-$296.80M	-$0.68	N/A	12.99	N/A	-7.21%	-9.23%	-5.45%	N/A
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-102.39%	-39.71%	N/A
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	112.09	N/A	N/A	N/A	N/A	8/20/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-41.35%	-35.53%	N/A

Latest SANA, TNGX, TLX, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2026	H1 2026	TLX Telix Pharmaceuticals	$0.0434	N/A	N/A	N/A	$479.63 million	N/A
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million
8/11/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/10/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LEGN Legend Biotech	N/A	2.13	2.05
SANA Sana Biotechnology	N/A	1.29	1.29
TLX Telix Pharmaceuticals	1.08	1.43	1.27
TNGX Tango Therapeutics	N/A	27.38	27.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LEGN Legend Biotech	70.89%
SANA Sana Biotechnology	88.23%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
LEGN Legend Biotech	0.02%
SANA Sana Biotechnology	25.40%
TLX Telix Pharmaceuticals	N/A
TNGX Tango Therapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A
TNGX Tango Therapeutics	90	168.61 million	135.25 million	Optionable

SANA, TNGX, TLX, and LEGN Headlines

Recent News About These Companies

Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX

3 hours ago | marketbeat.com

Tema ETFs LLC Buys New Holdings in Tango Therapeutics, Inc. $TNGX

August 13 at 5:28 AM | marketbeat.com

TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses

August 12 at 11:51 AM | zacks.com

Tango Therapeutics Q2 Net Loss Widens

August 11 at 7:13 PM | finance.yahoo.com

Tango Therapeutics Expands At-The-Market Equity Program

August 11 at 5:31 PM | tipranks.com

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results

August 11 at 9:40 AM | marketbeat.com

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

August 11 at 9:10 AM | markets.businessinsider.com

345,156 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Assenagon Asset Management S.A.

August 11 at 3:12 AM | marketbeat.com

Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure

August 9, 2026 | theglobeandmail.com

The Manufacturers Life Insurance Company Boosts Holdings in Tango Therapeutics, Inc. $TNGX

August 9, 2026 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Trading Down 6.1% - What's Next?

August 7, 2026 | marketbeat.com

Tango Therapeutics Announces Executive Chair Transition

August 6, 2026 | globenewswire.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of July

August 3, 2026 | seekingalpha.com

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

August 3, 2026 | zacks.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Moderate Buy" from Analysts

August 3, 2026 | americanbankingnews.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by Analysts

August 3, 2026 | marketbeat.com

Perceptive Advisors LLC Has $16.91 Million Stock Holdings in Tango Therapeutics, Inc. $TNGX

August 2, 2026 | marketbeat.com

Tango Therapeutics, Inc. $TNGX Stock Holdings Trimmed by Janus Henderson Group PLC

August 2, 2026 | marketbeat.com

DV Trading LLC Takes $6.29 Million Position in Tango Therapeutics, Inc. $TNGX

August 2, 2026 | marketbeat.com

Stempoint Capital LP Acquires Shares of 200,919 Tango Therapeutics, Inc. $TNGX

July 30, 2026 | marketbeat.com

ADAR1 Capital Management LLC Sells 90,021 Shares of Tango Therapeutics, Inc. $TNGX

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, TNGX, TLX, and LEGN Company Descriptions

Legend Biotech NASDAQ:LEGN

$20.27 -0.38 (-1.84%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$20.42 +0.16 (+0.76%)

As of 08:26 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Sana Biotechnology NASDAQ:SANA

$3.67 -0.10 (-2.65%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$3.64 -0.04 (-0.95%)

As of 08:30 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Telix Pharmaceuticals NASDAQ:TLX

$12.33 +0.36 (+3.01%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$11.94 -0.39 (-3.16%)

As of 08:08 AM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Tango Therapeutics NASDAQ:TNGX

$25.65 +0.07 (+0.27%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$25.78 +0.13 (+0.49%)

As of 08:18 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, TNGX, TLX, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, TNGX, TLX, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, TNGX, TLX, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, TNGX, TLX, and LEGN Company Descriptions

Legend Biotech NASDAQ:LEGN

Sana Biotechnology NASDAQ:SANA

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SANA, TNGX, TLX, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SANA, TNGX, TLX, and LEGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SANA, TNGX, TLX, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, TNGX, TLX, and LEGN Company Descriptions

Legend Biotech NASDAQ:LEGN

Sana Biotechnology NASDAQ:SANA

Telix Pharmaceuticals NASDAQ:TLX

Tango Therapeutics NASDAQ:TNGX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools